---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-026062"
form_type: "8-K"
ticker: "OFIX"
cik: "0000884624"
company_name: "Orthofix Medical Inc."
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T05:19:18.204367+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Orthofix reports record Q4 net sales of $215.7M (+8% YoY); guides FY25 sales $818-826M, adj. EBITDA $82-86M

## Summary
- Q4 net sales $215.7M (+8% YoY); record BGT $63.9M (+9%) and Global Orthopedics $35.8M (+18% cc).
- Q4 net loss $(29.1)M ($(0.75)/share); adjusted EBITDA $23.9M (11.1% margin) vs $19.6M (9.8%) in Q4 2023.
- FY24 net sales $799.5M (+7%); net loss $(126.0)M vs $(151.4)M; adjusted EBITDA $67.4M (8.4% margin) vs $46.3M.
- Discontinuing M6 artificial disc lines ($23.4M 2024 sales); guides FY25 sales $818-826M (ex-M6, +6.5% cc) and adj. EBITDA $82-86M.
- Long-term CAGR target raised to 6.5-7.5%; Q4 free cash flow $15.2M; cash $85.7M at year-end.

## SEC filing metadata
- accession: 0000950170-25-026062
- form_type: 8-K
- ticker: OFIX
- cik: 0000884624
- company_name: Orthofix Medical Inc.
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/884624/000095017025026062/0000950170-25-026062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/884624/000095017025026062/ofix-20250225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-026062
- JSON: https://secwatch.observer/filing/0000950170-25-026062.json
- Plain text: https://secwatch.observer/filing/0000950170-25-026062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.